Last update 11 Jan 2025

Rosabulin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Rosabulin (USAN), STA-5312
Target
Tubulin
Mechanism
Tubulin inhibitors
Therapeutic Areas
Neoplasms
Active Indication
Neoplasms
Inactive Indication
Advanced Malignant Solid NeoplasmLeukemiaLymphoma+ [1]
Originator Organization
Madrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.
Active Organization
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.
Inactive Organization
Synta Pharmaceuticals Corp.Synta Pharmaceuticals Corp.
Drug Highest PhasePreclinical
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H16N4O2S
InChIKeyIZZYUABKZYIINT-UHFFFAOYSA-N
CAS Registry501948-05-6

Related

2
Clinical Trials associated with Rosabulin
NCT00276913
/ CompletedPhase 1
A Phase I Study of STA-5312 Administered Weekly in Subjects With Advanced or Metastatic Solid Tumors
NCT00088101
/ CompletedPhase 1
Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
100 Clinical Results associated with Rosabulin
Login to view more data
100 Translational Medicine associated with Rosabulin
Login to view more data
100 Patents (Medical) associated with Rosabulin
Login to view more data
100 Deals associated with Rosabulin
Login to view more data

External Link

KEGGWikiATCDrug Bank
D06638---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
US
Synta Pharmaceuticals Corp.Synta Pharmaceuticals Corp.
01 Jun 2004
LeukemiaPhase 1
US
Synta Pharmaceuticals Corp.Synta Pharmaceuticals Corp.
01 Feb 2004
LymphomaPhase 1
US
Synta Pharmaceuticals Corp.Synta Pharmaceuticals Corp.
01 Feb 2004
Metastatic Solid TumorPhase 1
US
Synta Pharmaceuticals Corp.Synta Pharmaceuticals Corp.
01 Feb 2004
NeoplasmsPreclinical
US
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.
01 Apr 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASCO2006
Phase 1
Solid tumor
25
axhbqfrjxc(tjeefvnwps) = anemia, fatigue, constipation, nausea, and anorexia ihgofiqzpa (fzwaqtbkuc )
View more
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free